Research letterLack of evidence for feminization of males exposed to spironolactone in utero: A systematic review
Reference (13)
- et al.
Spironolactone therapy during human pregnancy
Am J Obstet Gynecol
(1995) - et al.
Low or high doses of spironolactone for treatment of maternal Barrter’s syndrome
Am J Obstet Gynecol
(1996) - et al.
Alcohol use prior to pregnancy recognition
Am J Prev Med
(1999) Aldactone [package insert]
(2008)U.S. Department of Health and Human Services website. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers
- et al.
Disturbances in sexual differentiation of rat foetuses following spironolactone treatment
Acta Endocrinol
(1980)
There are more references available in the full text version of this article.
Cited by (18)
Guidelines of care for the management of acne vulgaris
2024, Journal of the American Academy of DermatologyPrimary aldosteronism: Practical recommendations for treatment and follow-up
2023, Hipertension y Riesgo VascularPersonalized Treatment of Patients With Primary Aldosteronism
2023, Endocrine Practice2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2022, Journal of the American College of CardiologyEndocrine hypertension in pregnancy
2022, Endocrine Hypertension: From Basic Science to Clinical PracticeWhat the Pediatric and Adolescent Gynecology Clinician Needs to Know about Acne
2021, Journal of Pediatric and Adolescent GynecologyCitation Excerpt :There is no evidence of hyperkalemia in young and otherwise healthy women, and monitoring of potassium is not required in this population.50,51 In animals, male fetuses exposed to spironolactone showed feminization and the severity of genital dysmorphism was dose-dependent.52,53 There are few data on the use of spironolactone, which is off-label for all acne, in pre- and early-adolescence patients.
Funding sources: None.
Conflicts of interest: None disclosed.
© 2018 by the American Academy of Dermatology, Inc.